Abstract
Purpose of Review
Lupus nephritis flare is a frequent complication in patients with systemic lupus erythematosus. Recognizing disease activity is crucial in lupus nephritis management. Proteinuria magnitude and urine sediment change are major clinical indicators of lupus nephritis activity. This work updates these insights in light of recent findings regarding proteinuria quantification and urine sediment analyses.
Recent Findings
Currently, BILAG and SLEDAI estimate proteinuria magnitude based on the protein/creatinine ratio of “spot” (single void collections) or “intended” 24-h urine collections without specifying the extent to which the collection approaches a 24-h collection. As discussed here, and based on our recently published work, these approaches often incur serious errors that can adversely affect SLE patient management. Also incorporated into this work is a new analysis of the clinical significance of urine sediment hematuria and pyuria changes with regard to recent-onset SLE glomerulonephritis (GN) flare. This analysis is based on a prospective study of urine sediment changes in the Ohio SLE Study, which was an NIH-sponsored prospective observational study of SLE GN patients with SLE flare of recent onset.
Summary
We propose that BILAG and SLEDAI renal flare criteria can be made more rigorous by incorporating recently published insights into proteinuria quantification using the protein/creatinine ratio of an intended 24-h urine collection that is at least 50% complete based on its creatinine content. Also proposed are new insights into the interpretation of urine sediment hematuria and pyuria based on findings from the Ohio SLE Study.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Koopman MG, Krediet RT, Zuyderhoudt FJ, De Moor EA, Arisz L. A circadian rhythm of proteinuria in patients with a nephrotic syndrome. Clin Sci. 1985;69:395–401.
Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis :Off J Natl Kidney Found. 2006;47:8–14.
Fine DM, Ziegenbein M, Petri M, Han EC, McKinley AM, Chellini JW, et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 2009;76:1284–8.
Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, et al. Limited reliability of the spot urine protein/creatinine ratio in the longitudinal evaluation of patients with lupus nephritis. Kidney Int Rep. 2018;3:1057–63.
Group AT. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheum. 2014;66:3096–104.
Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol: JASN. 2003;14:3217–32.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ayoub, I., Birmingham, D., Rovin, B. et al. Commentary on the Current Guidelines for the Diagnosis of Lupus Nephritis Flare. Curr Rheumatol Rep 21, 12 (2019). https://doi.org/10.1007/s11926-019-0809-x
Published:
DOI: https://doi.org/10.1007/s11926-019-0809-x